PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-107.38%
Negative net income growth while VET stands at 77.50%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
0.99%
Less D&A growth vs. VET's 13.91%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-125.89%
Negative yoy deferred tax while VET stands at 2.53%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
-98.96%
Negative yoy working capital usage while VET is 147.64%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-98.96%
Negative yoy usage while VET is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
183.36%
Some yoy increase while VET is negative at -99.81%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-30.64%
Negative yoy CFO while VET is 19.34%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
23.31%
CapEx growth well above VET's 0.81%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
-292.73%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
97.30%
We have some outflow growth while VET is negative at -91.80%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-44.94%
Both yoy lines negative, with VET at -481.60%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
100.00%
Debt repayment growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.